Wegovy Korean Version — GLP-1 Weight Management Injection
- GLP-1 receptor agonist — regulates appetite signaling and delays gastric emptying
- Clinically proven: 15% mean body weight reduction over 68 weeks
- 5-step dose escalation protocol to minimize GI intolerance
- Improves cardiometabolic markers (BP, LDL-C, HbA1c)
- Single-use prefilled pen for once-weekly subcutaneous administration
- Korean Version — cost-effective alternative with same active ingredient
| 1 - 2 boxes | $560.00 / box |
| 3 - 9 boxes | $532.00 / box |
| 10 - 19 boxes | $504.00 / box |
| 20 - 29 boxes | $487.20 / box |
| 30+ boxes | Contact for quote |
What Is Wegovy Korean Version — GLP-1 Weight Management Injection?
Wegovy® (semaglutide) — a GLP-1 receptor agonist for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities. Clinical trials demonstrate 15% mean body weight reduction over 68 weeks. Korean Version.
Wegovy® is a GLP-1 receptor agonist for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia). The Korean Version offers a cost-effective alternative with the same active ingredient (semaglutide) and comparable efficacy. Clinical trials demonstrate a mean 15% body weight reduction (35 lb from 232 lb baseline) over 68 weeks, with 86% of patients achieving ≥5% weight loss and 30% achieving ≥20% weight loss. The 5-step dose escalation protocol (over 20 weeks) minimizes GI intolerance while optimizing therapeutic outcomes. Beyond weight loss, Wegovy improves cardiometabolic markers including blood pressure, LDL cholesterol, and HbA1c, supporting long-term weight maintenance when combined with lifestyle interventions.
Specifications
| Product name | Wegovy Korean Version |
|---|---|
| Brand | Novo Nordisk (Korean Version) |
| Type | GLP-1 receptor agonist weight management injection |
| Active ingredient | Semaglutide |
| Mechanism | GLP-1 receptor agonist — regulates hypothalamic appetite signaling, delays gastric emptying |
| Presentation | 5 single-use prefilled pens per box (5-step dose escalation) |
| Concentration | 0.25mg, 0.5mg, 1.0mg, 1.7mg, 2.4mg per pen |
| Administration | Subcutaneous injection once weekly |
| Dosage protocol | 5-step escalation over 20 weeks (0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg) |
| Treatment | Chronic weight management (BMI ≥30 or BMI ≥27 with comorbidities) |
| Duration | 68-week program (long-term maintenance available) |
| Origin | South Korea |
| Storage | 2–8°C. Do not freeze. |
Key Benefits
- Significant weight loss — 86% of patients achieve ≥5% weight loss
- Sustained results — 2-year extension shows maintained 15% weight control
- Multi-system benefits — improves BP, lipids, and HbA1c
- Convenient once-weekly dosing with simple dose escalation
- Cardiovascular protective effects beyond weight reduction
Suggested Treatment Protocol
Wegovy uses a 5-step dose escalation protocol to minimize GI intolerance: Weeks 1–4: 0.25mg once weekly. Weeks 5–8: 0.5mg once weekly. Weeks 9–12: 1.0mg once weekly. Weeks 13–16: 1.7mg once weekly. Week 17 onwards: 2.4mg once weekly (maintenance dose). Administer subcutaneously in the abdomen, thigh, or upper arm on the same day each week. Rotate injection sites. If a dose is missed, administer within 5 days; if more than 5 days have passed, skip the missed dose and resume the regular schedule.
Frequently Asked Questions
What is Wegovy Korean Version?
Wegovy Korean Version is a GLP-1 receptor agonist containing semaglutide, used for chronic weight management. It is the Korean-sourced version of the original Wegovy formulation, offering the same active ingredient at a competitive price point.
How does Wegovy work?
Wegovy works by mimicking the GLP-1 hormone, which regulates appetite by signaling the brain that you are full. It also slows gastric emptying, helping you feel fuller longer and consume fewer calories.
What is the dosing schedule?
Wegovy uses a 5-step dose escalation protocol over 20 weeks: starting at 0.25mg once weekly and gradually increasing to the maintenance dose of 2.4mg once weekly. Each box contains 5 pens for the full escalation protocol.
Who is Wegovy for?
Wegovy is indicated for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or high cholesterol.
What results can I expect?
Clinical trials show a mean 15% body weight reduction (approximately 35 lb from a 232 lb baseline) over 68 weeks. 86% of patients achieved ≥5% weight loss, and 30% achieved ≥20% weight loss.
How should Wegovy be stored?
Store Wegovy pens in the refrigerator at 2–8°C. Do not freeze. Keep the pens in the original carton to protect from light. Each pen is single-use and should be discarded after use.
Very satisfied with this product. The 15% mean weight reduction from clinical trials is achievable in practice. Combined with lifestyle counseling, outcomes are excellent. Will continue to purchase.
Excellent product for weight management. The dose escalation protocol is well-designed and patients report minimal GI side effects when followed correctly. The Korean version offers the same efficacy at a more accessible price point.
Great value for a GLP-1 therapy. The Korean Version provides significant cost savings without compromising quality. Patients tolerate the medication well when following the recommended dose escalation protocol.
Highly effective GLP-1 therapy. My patients have achieved remarkable results with the 5-step titration schedule. Results are visible within the first 4 weeks at 0.25mg. Highly recommend for motivated patients.
Wegovy Korean Version has been a game-changer for my weight management clinic. Consistent supply and quality. The once-weekly dosing improves patient compliance significantly compared to daily medications.
Please log in to leave a review.